Case Series

Primary tumor resection of metastatic gastric cancer in a multimodal era: Two case reports

Flavio Roberto Takeda, Rodrigo Nicida Garcia, Serli Kiyomi Nakao Ueda, Renata D’Alpino Peixoto, Rubens Antonio Assar Sallum, Ivan Cecconello

A R T I C L E   I N F O

Article history:
Received 22 July 2020
Accepted 16 August 2020
Available online 29 August 2020

Keywords:
Metastatic gastric cancer
Surgical resection
Neoadjuvant chemotherapy

A B S T R A C T

INTRODUCTION: Although no consensus has been reached on the role of surgical treatment for metastatic gastric cancer, some reports suggest promising results on patients with a small disease volume upon presentation. We present two cases of metastatic disease with a favorable outcome following surgical treatment.

PRESENTATION OF CASES: The first case presented with an adenocarcinoma of the cardia, which was staged as oligometastatic due to a small liver nodule on segment III. Treatment consisted of neoadjuvant chemotherapy followed by laparoscopic esophagectomy and hepatectomy. The patient remains disease-free 62 months after surgery. Unlike the first case, the second case presented with a large number of liver nodules upon diagnosis, ruling out metastasectomy as a possible treatment. The tumor expressed HER2 receptors and responded favorably to chemotherapy plus trastuzumab for 34 months. At this point, disease progression was observed on the primary site, but the hepatic lesions remained stable. The patient underwent gastrectomy, resumed the chemotherapy regimen, and had a favorable outcome, with stability of the liver metastasis and no local recurrence following primary tumor resection.

DISCUSSION: We illustrate through these two cases the effectiveness of a combined approach featuring perioperative chemotherapy and radical surgery for selected cases of oligometastatic gastric cancer, which we hope will spur further research on the topic.

CONCLUSION: Systemic treatment in metastatic gastric cancer may represent a novel treatment approach that allows surgical resection of the primary tumor in select cases.

© 2020 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Historically, the presence of metastasis in gastric cancer signifies ineligibility for surgical treatment and led to a marked decrease in overall survival [1,2]. Recent advancements in systemic therapies leading to better disease control have motivated a renewed discussion surrounding the role of surgical resection in metastatic gastric cancer [3]. The following two cases, which illustrate this new paradigm, are reported in line with the SCARE criteria [4], and illustrate this new paradigm.

1.1. Case 1

A 68-year-old woman presented with dysphagia and unquantified weight loss. She had a history of smoking, mild asthma, and dyslipidemia.

Upper digestive tract endoscopy revealed an infiltrative lesion extending from the distal esophagus into the cardia that was diagnosed through biopsy as an adenocarcinoma. Positron emission tomography–computed tomography (PET–CT) revealed elevated metabolism in perigastric lymph nodes, as well as a small nodule on hepatic segment III (Fig. 1A–D). Endoscopic ultrasonography characterized the lesion as uST3 N+.

A decision was made for chemotherapy with neoadjuvant intent. The selected regimen comprised three cycles of capecitabine
(2000 mg/m²/d × 14) + cisplatin (70 mg/m² × 1). On re-staging, a remarkable decrease in volume of both the primary lesion and the secondary hepatic nodule were observed (Fig. 1E, F), motivating surgery with curative intent.

The patient underwent total gastrectomy and transhiatal esophagectomy, followed by wedge resection of the liver lesion on segment III. The postoperative period was uneventful, and the patient was discharged on the 13th postoperative day. Adjuvant chemotherapy was initiated 49 days after surgery, with two cycles of the same regimen administered preoperatively, which was interrupted by neutropenia.

Repeat imaging was performed every six months for the first two years, and once annually thereafter. As of the writing of this report, the patient has been followed for 56 months, throughout which the patient has remained disease-free. In regard to quality of life, the patient still presents symptoms of gastroesophageal reflux, but reports no other complaints. Furthermore, the patient is accepting oral intake with no restrictions and maintaining basal weight.

1.2. Case 2

A 75-year-old male presented with upper abdominal discomfort and a dry cough. He had a history of coronary heart disease and two previous stent angioplasties. Initial laboratory testing revealed anemia (Hb =9.0 mg/dL), and CT scanning of the chest was unremarkable other than multiple liver nodules. Abdominal magnetic resonance imaging (MRI) revealed gastric wall thickening in the smaller curvature with infiltration of the adjacent fat tissue measuring up to 8.2 cm, as well as the aforementioned multiple liver nodules (Fig. 2). Upper tract digestive endoscopy indicated an 6-cm infiltrative lesion on the anterior gastric wall and along the smaller curvature. Biopsy confirmed adenocarcinoma with HER2 expression. Serum CEA on diagnosis was 665.9 mg/dL.

The patient underwent nine cycles of FOLFOX associated with targeted therapy with trastuzumab. The response was favorable, with the size of the hepatic nodules decreasing significantly to 2.5 cm and with CEA dropping to 8.28, representing a 98.8% decrease. The regimen was altered to 5-FU + trastuzumab and maintained for a total of 63 additional cycles over 34 months, with a satisfactory response and hepatic nodules reaching a size of 1.3 cm. After this point, the gastric lesion showed growth despite stability of the liver nodules. In the face of localized disease progression, a decision was made for surgical resection.

The patient underwent partial gastrectomy with D2 lymphadenectomy and Roux-en-Y reconstruction. The surgical specimen was staged as ypT3 ypN1 (2/18). Chemotherapy was resumed postoperatively with the same regimen.

As of the writing of this article, the patient has been followed for 49 months since the beginning of the treatment, and 14 months since surgery. The patient remains under the same chemotherapy regimen, with minor toxicity-related symptoms (G1 neuropathy). The patient is reportedly content with the treatment approach, and no signs of disease progression have been observed on any site thus far.

2. Discussion

Metastatic disease is present on diagnosis in up to 32.6% of all gastric cancer cases and represents a poor prognosis factor, with overall survival ranging from 4 to 5 months [1,2]. To date, there is no international consensus establishing the role of surgery in the metastatic scenario. Notably, Japanese studies generally issue a weak recommendation for hepatectomy in patients with a small number of metastases and no other incurable factors [5], while the ESMO guidelines recommend against metastasectomy on the grounds that it does not improve survival [6]. Nevertheless, several retrospective studies point towards a survival benefit associated with surgical therapies for metastatic disease [7–16], particularly when R0 resection can be achieved [17]. Additionally, the FLOT3 trial showed a survival benefit in patients subjected to surgical resection of metastatic lesions after neoadjuvant chemotherapy [18]. Ongoing studies are further investigating this treatment modality, such as the FLOT5 and the SURGIGAST trial.

The idea of oligometastatic disease as distinct from both localized and advanced disease was first proposed in 1995 and has since been used as a model to explain the prolonged disease-free survival observed in some patients who undergo metastasectomies. Multiple definitions have been proposed for oligometastasis, all of which
center around a small number of metastases that are restricted to one or two sites. While definitive proof of the validity of such a concept remains to be reached, molecular findings suggest differing tumor biologies between multiple and oligometastatic cancers [19].

In the first case presented, the patient had metastatic disease on diagnosis, which was restricted to a single liver metastasis of a small diameter, in line with favorable prognosis factors described in the current literature [19]. A favorable response to neoadjuvant chemotherapy further reinforced that this case was a good candidate for resection. The results, as reflected by prolonged survival relative to what is usually expected for metastatic disease, support the current trends regarding the treatment of oligometastatic gastric cancer.

The second case illustrates a tailored approach to a heterogeneous tumoral response to systemic treatment. The patient presented with a large volume of disease in the liver that was considered unresectable on diagnosis. After an initially excellent response to chemotherapy associated with anti-HER2 therapy, there was disease progression restricted to the primary site, while liver disease was stable. Surgical approach proved effective, and the metastatic lesions remained responsive to systemic treatment after removal of the primary site.

Although gastrectomy in the context of metastatic disease has been discouraged since the results of the REGATTA trial [20], which showed no survival benefit for gastrectomy following chemotherapy relative to systemic treatment alone, this particular case benefitted from the approach, warranting further investigation of the possibility of heterogeneous response across multiple sites.

3. Conclusion

Although not reflected in current guidelines, oligometastatic gastric cancer appears to possess a distinct course and etiology in which surgical treatment could play a significant role. The cases presented serve as two examples of surgical intervention yielding survival times longer than would have been expected with systemic treatment exclusively.

As mentioned, the current literature houses a compelling repertoire of retrospective studies on this topic, but few controlled clinical trials. More studies of this type are needed to formulate practice guidelines. We expect the upcoming results of the FLOTS and SURGIGAST trials to bring further advancements on this front.

Declaration of Competing Interest

The authors report no declarations of interest.

Funding

The authors received no specific funding for this work.
Ethical approval

Ethical approval exemption was given for this study.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Author's contribution

Flavio Roberto Takeda: Conceptualization, writing, formal analysis.

Rodrigo N Garcia: writing – review and editing.

Serli Kiyomi Nakao Ueda: writing – review and editing radiological images.

Renata D’Alpino Peixoto: writing – review and editing.

Rubens Antonio Aissar Sallum: writing and Supervision.

Ivan Cеццоноло: Supervision.

Registration of research studies

Not applicable.

Guarantor

Flávio Roberto Takeda.

Provenance and peer review

Not commissioned, externally peer-reviewed.

References

[1] D. Yang, A. Hendifar, C. Lenz, et al., Survival of metastatic gastric cancer: significance of age, sex and race/ethnicity, J. Gastrointest. Oncol. 2 (2) (2011) 77–84, http://dx.doi.org/10.3978/j.issn.2078-6891.2010.025.

[2] Y. Zhang, Y. Lin, J. Duan, K. Xu, M. Mao, X. Wang, A population-based analysis of distant metastasis in stage IV gastric cancer, Med. Sci. Monit. 26 (2020), e923867, http://dx.doi.org/10.12659/MSM.923867, Published 2020 May 15.

[3] Jin-On Jung, Henrik Nienhäuser, Nikolai Schleusner, Thomas Schmidt, Oligometastatic gastroesophageal adenocarcinoma: molecular pathophysiology and current therapeutic approach, Int. J. Mol. Sci. 21 (January 3) (2020), http://dx.doi.org/10.3390/ijms21030951, pii: E951.

[4] R.A. Agha, A.J. Fowler, A. Saetta, I. Barai, S. Rajnossan, D.P. Orgill, for the SCARE Group, The SCARE 2018 statement: updating consensus Surgical Case Report (SCARE) guidelines, The SCARE Statement: Consensus-based surgical case report guidelines. International Journal of Surgery 2018, Int. J. Surg. 60 (2018) 122–136.

[5] Japanese Gastric Cancer Association, Japanese gastric cancer treatment guidelines 2018 (5th edition), published online ahead of print, 2020 Feb 14, Gastric Cancer (2020), http://dx.doi.org/10.1007/s10120-020-01042-y.

[6] E.C. Smyth, M. Verheij, W. Allum, et al., Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol. 27 (suppl. 5) (2016) v38–v49, http://dx.doi.org/10.1093/annonc/mdw350.

[7] Hiromichi Ito, Nobuyuki Takamura, Yoshihiro Ono, Takafumi Sato, Yoshihiro Mise, Yosuke Inoue, Yu Takahashi, Akio Saiura, Gastric cancer liver metastasis: optimal management for oligo-metastatic disease, J. Clin. Oncol. 37 (4_suppl) (2019), 136–136.

[8] B. Badgwell, S. Roy-Chowdhuri, Y. Chiang, et al., Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery, J. Surg. Oncol. 115 (2015) 875–881.

[9] A. Carmona-Bayonas, P. Jiménez-Fonseca, I. Echavarria, et al., Surgery for metastases for oligometastatic gastric cancer in the real world: data from the AGAMENON national registry, Eur. J. Surg. Oncol. 44 (8) (2018) 1191–1198, http://dx.doi.org/10.1016/j.ejso.2018.03.019.

[10] T. Kinoshita, T. Kinoshita, A. Sairua, M. Esaki, H. Sakamoto, T. Yamanaka, Multicentre analysis of long-term outcome after surgical resection for gastric cancer liver metastases, Br. J. Surg. 102 (1) (2015) 102–107, http://dx.doi.org/10.1002/bjs.9684.

[11] K. Kawahara, H. Makino, H. Kamekata, et al., Outcomes of surgical resection for gastric cancer liver metastases: a retrospective analysis, World J. Surg. Oncol. 18 (1) (2020) 41, http://dx.doi.org/10.1186/s12957-020-01816-9, Published 2020 Feb 24.

[12] S. Ministrini, L. Soliani, C. Cipollari, S. Sofia, E. Marino, A. D’Ignazio, M. Bencivenga, G.A.M. Tiberio, Surgical treatment of hepatic metastases from gastric cancer, Update Surg. 70 (2018) 273–278.

[13] S.R. Markar, H. MacKenzie, S. Mikhail, M. Mughal, S.R. Preston, N.D. Maynard, O. Faiz, G.B. Hanna, Surgical resection of hepatic metastases from gastric cancer: outcomes from national series in England, Gastric Cancer 20 (2016) 79–86.

[14] E. Oki, Kyushu Study Group of Clinical Cancer, S. Tokunaga, Y. Emi, T. Kusumoto, M. Yamamoto, K. Fukuzawa, I. Takahashi, S. Ishigami, A. Tsuji, et al., Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302), Gastric Cancer 19 (2015) 968–976.

[15] G. Tiberio, S. Ministrini, A. Gardini, D. Marrelli, A. Marchet, C. Cipollari, L. Graziosi, C. Pedrazzani, G.L. Baiocchi, G. La Barba, et al., Factors influencing survival after hepatectomy for metastases from gastric cancer, Eur. J. Surg. Oncol. (EJSO) 42 (2016) 1229–1235.

[16] N. Takemura, A. Saiura, R. Koga, R. Yoshioka, J. Yamamoto, N. Kokudo, Repeat hepatectomy for recurrent liver metastasis from gastric carcinoma, World J. Surg. 37 (2013) 2664–2670.

[17] S.R. Markar, S. Mikhail, G. Malietzis, T. Athanasiou, C. Mariette, M. Sasaki, G.B. Hanna, Influence of surgical resection of hepatic metastases from gastric adenocarcinoma on long-term survival: systematic review and pooled analysis, Ann. Surg. 263 (2016) 1102–1101.

[18] S.-E. Al-Batran, N. Homann, C. Pauligk, G. Illerhaus, U.M. Martens, J. Stoechlmacher, H. Schmaalenberg, K.B. Luley, N. Prasnikar, M. Egger, et al., Effect of neo-adjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial, JAMA Oncol. 3 (2017) 1237–1244.

[19] P. Jin, X. Ji, Y. Tian, Surgical management of oligometastatic disease in gastric cancer [published online ahead of print, 2020 Mar 5], Clin. Res. Hepatol. Gastroenterol. (2020), http://dx.doi.org/10.1016/j.clinre.2020.02.003, S2210-7401(20)30036-X.

[20] K. Fujitani, H.K. Yang, J. Mizusawa, et al., Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial, Lancet Oncol. 17 (3) (2016) 309–318, http://dx.doi.org/10.1016/S1470-2045(15)00553-7.

Open Access

This article is published Open Access at sciencedirect.com. It is distributed under the JJSCR Supplemental terms and conditions, which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.